Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modern computational chemistry and drug discovery: structure generating programs

R S Bohacek1, C McMartin

  • 1ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.

Current Opinion in Chemical Biology
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery.

Medicinal chemistry (Shariqah (United Arab Emirates))·2006
Same author

Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design.

Journal of medicinal chemistry·2001
Same author

A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain.

Bioorganic & medicinal chemistry letters·2001
Same author

Aspartic protease inhibitors designed from computer-generated templates bind as predicted.

Organic letters·2001
Same author

Design and synthesis of unsymmetrical peptidyl urea inhibitors of aspartic peptidases.

Organic letters·2001
Same author

X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor.

Journal of medicinal chemistry·2001

De novo design methods create novel enzyme inhibitors and improve HIV protease inhibitors by computationally designing molecules to fit specific binding sites. These computational approaches are advancing drug discovery by generating virtual libraries for identifying potential drug candidates.

Area of Science:

  • Medicinal Chemistry
  • Computational Drug Design
  • Structural Biology

Background:

  • Enzyme inhibitors are crucial for therapeutic interventions.
  • Traditional drug design often relies on modifying existing compounds.
  • The need for novel chemical structures with high binding affinity is persistent.

Purpose of the Study:

  • To highlight the emergence and application of de novo design methods in creating novel enzyme inhibitors.
  • To demonstrate the utility of de novo approaches in enhancing the binding affinity of existing drugs, such as HIV protease inhibitors.
  • To outline ongoing advancements in de novo design, focusing on generating synthetically feasible and complementary molecular structures for specific binding sites.

Main Methods:

  • De novo computational methods for designing novel molecular structures.

Related Experiment Videos

  • Structure-based drug design principles to complement binding sites.
  • Development of algorithms for generating synthetically feasible molecules.
  • Creation of virtual molecular libraries for drug candidate screening.

    • Main Results:

    • The first reports of active enzyme inhibitors designed entirely by de novo methods emerged in 1996-1997.
    • De novo design successfully improved the binding affinity of an HIV protease inhibitor.
    • Algorithms capable of generating synthetically feasible structures have been developed.
    • Methods for automated generation of virtual libraries for pharmacophore matching are under development.

    Conclusions:

    • De novo design represents a powerful strategy for discovering novel enzyme inhibitors.
    • Computational approaches are significantly advancing the optimization of drug candidates.
    • The development of de novo algorithms enhances the efficiency and feasibility of drug discovery pipelines.